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Intraoperative magnetic resonance imaging-assisted
transsphenoidal pituitary surgery in patients with acromegaly
Abstract
In this largest study to date of GH-producing pituitary adenomas in which iMR imaging-guided
transsphenoidal surgery was analyzed, the results suggest that this method is a highly effective and safe
treatment modality, even compared with previously published surgical series in which high-field iMR
imaging was used. Limitations of iMR imaging are the detection of small residual tumor in the
cavernous sinus and persisting disease that could not be observed, even on diagnostic high-field
follow-up MR images. This points to a general limitation regarding remission rates that can be achieved
using iMR imaging. Nevertheless, iMR imaging led to an increase of the remission rate in this study.
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AcromegAly is a rare disease, with an estimated incidence of approximately 4 cases per 1 million population. In most cases, it is caused by a GH-pro-
ducing pituitary adenoma. If excessive output of GH is not 
normalized, severe cardiovascular and metabolic distur-
bances as well as cosmetic and orthopedic deformities will 
result. Previously published studies have shown a 2–3-fold 
increased mortality rate for treatment-resistant cases, com-
pared with successfully treated patients and healthy indi-
viduals.6,28,36 Correction of GH values to normal can restore 
life expectancy toward normal. Most studies and the inter-
national consensus conference8,12,26,27 recommend surgery 
as the first-line treatment. Medication with somatostatin 
analogs can achieve biochemical control in up to 60% of 
cases, but without comparable tumor size reduction. The 
first surgical treatment in which a transnasal approach was 
used in a patient with acromegaly was performed by Dr. 
Schloffer in Vienna in 1907.31 Two years later, Dr. Cushing 
did a partial hypophysectomy in a patient with acromegaly, 
assuming that the underlying pathological mechanism was 
a hypertrophy of the pituitary gland.10 Surgical techniques 
and nonsurgical treatment options have been developing 
ever since.23 Today, most patients receive surgery as the 
first-line treatment, via a transnasal, transsphenoidal ap-
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proach that was introduced by Cushing and then reintro-
duced using microsurgical techniques by Hardy in 1979.18 
More recently developed refinements in this surgical ap-
proach include the introduction of endoscopy3,9,20,22 for pi-
tuitary surgery, and iMR imaging.4,14 In this largest study 
to date in which ultra-low-field iMR imaging was used in 
patients with GH-producing pituitary adenomas, we retro-
spectively analyzed a series of 39 consecutive cases that 
had been treated using a transnasal, transsphenoidal micro-
surgical iMR imaging–assisted approach with the PoleStar 
N20 unit (0.15 T).
Methods
Patient Demographic Data
Thirty-nine surgical interventions were performed in 
37 patients (24 men and 13 women) suffering from GH-
producing pituitary adenomas between September 2005 
and August 2009 (Table 1). Two patients (1 man and 1 
woman) were treated twice. All patients underwent trans-
sphenoidal surgery performed by the senior author (R.L.B.) 
with the aid of ultra-low-field iMR imaging. The mean pa-
tient age was 47 ± 14 years (median 46 years, range 19–
76 years). The median preoperative tumor size was 1319 
mm3 (mean 3360 mm3, range 50–56,549 mm3). Ten cases 
(25.6%) presented with microadenomas, 27 (69.2%) with 
macroadenomas, and 2 (5.1%) with giant adenomas. There 
were 5 patients (12.8%) with previous pituitary surgery. In 
10 cases (25.6%) the tumor invaded the cavernous sinus. In 
37 cases (94.8%), patients had symptoms of acromegaly, 
and 8 patients (20.5%) had cranial nerve symptoms, among 
them 5 with visual field deficits (Table 2). 
Preoperative and Postoperative Management
Patients were seen as outpatients before surgery. After 
the decision to proceed with surgical treatment, patients 
were admitted to the hospital the day before surgery. Pre-
operative diagnostic tests included CT scanning and MR 
imaging for determination of the characteristics of the pi-
tuitary adenoma as well as bone and neurovascular struc-
tures. Preoperative and postoperative imaging studies were 
performed at the Department of Neuroradiology, Univer-
sity Hospital Zurich. The CT studies were performed on 
a 16-slice CT scanner (Siemens SOMATON Sensation), 
acquiring multislice imaging data with and without the ad-
dition of contrast material. The MR imaging studies were 
performed on a 1.5-T MR unit (Signa, General Electric).
Neurological and ophthalmological examinations 
were performed after admission. General patient data, 
additional diagnosis, medication at admission, and previ-
ous study results were noted. Patients underwent endocri-
nological examination, which included blood analysis for 
pituitary function in which GH, IGF-I, adrenocorticotro-
pic hormone, cortisol, TSH, fT4, fT3, PRL, luteinizing 
hormone, follicle-stimulating hormone, and human chori-
onic gonadotropin were examined; testosterone was mea-
sured in male patients and estradiol in female patients, 
unless there was a history of recent menstrual bleeding or 
of contraceptive pill use (Table 3). 
Patients signed consent forms for the surgical proce-
dure and general anesthesia. On the day of surgery most 
patients received, for safety reasons, 100 mg of hydro-
cortisone (SoluCortef, Pfizer) 1 hour before operation; 
another 100-mg dose of hydrocortisone was adminstered 
perioperatively. After surgery, patients were transferred to 
an intermediate care unit. A postoperative CT scan was 
obtained in all patients approximately 6 hours after sur-
gery to exclude major bleeding or serious complications. 
The next morning, patients were transferred to the general 
ward and mobilized. They received 100 mg of hydrocor-
tisone on the 1st postoperative day and 50 mg on the 2nd 
postoperative day. On the morning of the 3rd postoperative 
day and/or before discharge, their pituitary function was 
reexamined. If patients’ cortisol levels were < 200 nmol/L 
in early morning blood samples, they received 30 mg of 
hydrocortisone (Hydrocortone, Merck) per day until endo-
crinological follow-up evaluation as outpatients 4 weeks 
after surgery.
Surgery and Intraoperative Neuroimaging
All operations were performed after induction of 
general anesthesia. Patients were placed supine on a fold-
able standard operating table, with their heads slightly 
reclined. The head was then fixed in an MR imaging–
compatible head holder, after adjusting the radiofre-
quency coil around the patient’s head. Subsequently, the 
preoperative CT studies were referenced with the intra-
operative navigation system (StealthStation, Medtronic 
Navigation). The iMR imager used in all patients was a 
PoleStar N20 (0.15 T, Medtronic Navigation). The posi-
tion of the patient’s head in the scanner was tested by per-
forming a 24-second sagittal e-steady scan (8-mm slices) 
and adjusted if necessary. Before surgery, a 7-minute, 
T1-weighted, Gd-enhanced (20 ml; Dotarem, Guerbet), 
4-mm-slice, coronal iMR image was obtained. These im-
ages were automatically loaded into the navigation sys-
tem and merged with the preoperative imaging studies.
All parts of the surgical procedures were performed 
with the aid of an operating microscope (Pentero, Carl 
Zeiss). At the beginning of the operation, a self-retaining 
endonasal speculum was inserted in the nostril chosen for 
the surgical approach. The mucosa was incised and par-
tially removed, the posterior bony part of the septum was 
removed, and the anterior wall of the sphenoid sinus was 
displayed. The anterior wall of the sphenoid sinus was 
then opened with punches, the intrasphenoidal mucosa 
and septum were removed, and the inferior and anterior 
surface of the sella turcica was displayed and opened with 
a chisel. The dura mater was opened in an X-shaped fash-
ion, and the adenoma was removed by curettes, grasping 
forceps, and suction devices. Tumor material was sent for 
frozen sections and neurohistopathological examination. 
After complete tumor removal was accomplished 
according to the surgeon’s impression, a 3.5-minute, T1-
weighted, Gd-enhanced, 4-mm-slice, coronal iMR image 
was obtained for resection control in all patients. For better 
visualization of possible tumor remnants, a glove-covered 
ball of bone wax was inserted into the resection cavity 
for hemostasis and improved interpretation of intraopera-
tive images. The intraoperatively acquired images were 
automatically merged with the existing preoperative and 
intraoperative imaging studies. In cases of visible tumor 
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remnants, the resection cavity was reexamined and tumor 
remnants removed if possible. Another postresection, intra-
operative, 3.5-minute, T1-weighted, Gd-enhanced, 4-mm-
slice, coronal iMR image was obtained in those cases. The 
anterior wall of the sella turcica was reconstructed using 
the extracted posterior part of the bony nasal or intrasphe-
noidal septum. In cases of intraoperative CSF leakage, the 
sella was packed with abdominal fat, and fibrin sealant was 
used. No nasal packing was used. All operations were per-
formed by the senior author (R.L.B.).
TABLE 1: Overview of data in 37 patients with acromegaly*
Case 
No.
Age 
(yrs), 
Sex
Prev 
Op
Dur 
of Op 
(min)
LOS 
(days)
Tumor 
Vol 
(mm3) HC AR
Remnant 
at EOS
Remnant 
at FU
RS at 
FU (mm3)
Preop Level (μg/ml) Postop Level (μg/ml)
Pt in 
RemissionGH IGF-I GH IGF-I
1 46, M yes, 1 105 6 506 B no no yes 220 1.44 281 6.13 371 no
2 29, M no 180 7 268 E no no no NA 31.20 996 0.12† 328 yes
3 70, M no 116 6 785 B no no no NA 14.00 544 3.30 19 no
4 66, F no 90 7 523 A no no no NA 7.97 776 — 350 yes
5 64, M no 60 8 829 B no no no NA 31.20 709 1.00† 152 yes
6 42, M no 125 6 1,993 C yes no yes 4 88.20 779 5.06 213 no
7 39, M no 115 7 2,278 C no no no NA 25.40 859 0.45† 330 yes
8 52, M no 95 8 1,334 B no no no NA 10.60 765 0.48 175 yes
9 32, M no 120 6 3,364 C no no no NA 107.00 1,308 0.42 193 yes
10 64, M no 50 6 91 A no no no NA 6.21 472 0.26 142 yes
11 43, F no 60 12 226 A no no no NA 12.80 564 1.64 179 no
12 44, F no 75 8 1,238 B no no no NA 20.30 461 0.48 218 yes
13 66, M no 170 9 1,851 C no no no NA 24.90 848 <1.00† 304 yes
14 51, F no 95 7 2,948 C yes no no NA 49.00 1,007 0.66† 431 yes
15 37, M no 95 5 4,158 C no no yes 168 28.40 1,307 3.09 405 no
16 38, M yes, 1 60 7 167 A no no no NA 1.34 245 0.82 181 yes
17 38, F no 40 8 1,319 B no no no NA 4.52 382 0.30 172 yes
18 19, F no 100 17 13,722 D yes no yes 147 438.00 900 6.84 835 no
19 20, F yes, 1 140 7 307 B yes no yes 52 15.90 702 4.39 735 no
20 32, M no 85 8 4,576 C no no no NA 23.40 1,085 0.51 251 yes
21 49, M no 105 8 5,091 D yes no yes 4 39.00 926 1.51† 317 no
22 76, F no 45 7 518 A no no no NA 24.60 580 0.08† 194 yes
23 74, M no 55 8 691 B no no no NA 27.40 1,020 2.00 206 yes
24 53, F no 100 7 2,741 B yes no no NA 47.00 932 0.84 196 yes
25 49, M no 145 9 7,225 E yes no yes 4 12.30 801 6.23 376 no
26 58, M no 75 7 131 A no no no NA 23.00 140 1.38 409 no
27 45, M no 140 9 50 A no no no NA 5.09 801 0.42 394 yes
28 54, M no 50 6 424 A no no no NA 6.85 553 0.42 278 yes
29 44, F no 30 7 2,356 C no no no NA 14.40 1,158 1.05 351 no
30 28, M no 55 5 1,876 C no no no NA 84.50 992 0.10 345 yes
31 53, F no 55 8 314 A no no no NA 5.42 527 0.85 170 yes
32 30, M no 58 8 1,238 B no no no NA 47.90 1,349 <1.00† 603 yes
33 64, F no 50 8 226 A no no no NA 4.13 403 0.85 151 yes
34 45, F yes, 2 60 10 301 A no no no NA 1.53 447 1.40 439 no
35 30, M no 70 6 1,810 B no no no NA 18.10 1,053 0.14 260 yes
36 53, F no 115 7 3,064 C no no no NA 10.00 380 0.39† 165 yes
37 51, F no 100 7 2,089 C no no no NA 19.50 1,112 0.52† 359 yes
38 41, M yes, 1 235 7 56,549 D yes yes yes 4691 15.40 1,081 3.90 480 no
39 48, M no 60 6 1837 C no no no NA 6.58 807 0.04 137 yes
*  Two patients underwent a second surgery. Abbreviations: AR = additional tumor removal after first iMR session for resection control; Dur = duration; 
EOS = end of surgery; FU = follow-up; HC = Hardy classification; LOS = length of stay; NA = not applicable; Pt = patient; RS = remnant size. 
†  Values are results of GTTs; other values are baseline results.
D. Bellut et al.
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Follow-Up Protocol and Classification of Findings
All patients were followed-up 4 weeks postopera-
tively as outpatients in the endocrinology clinic; hormone 
levels were analyzed and deficient hormones were re-
placed if necessary. Three months after surgery, patients 
underwent a postoperative MR imaging study for resec-
tion control, and were seen for neurosurgical follow-up 
and examination. Patients were only defined as being in 
remission if symptoms of acromegaly disappeared, IGF-I 
levels returned to the age-adjusted reference range, and 
GH levels decreased to < 1 mg/L. In cases of clinical im-
provement and normalization of IGF-I levels, but with 
GH levels between 1 and 5 mg/L, a GTT was performed. 
Patients suppressing GH to < 1 mg/L on the GTT were 
defined as being in remission as well.
Statistical Analysis and Neuroimaging
The statistical analysis was performed using Microsoft 
Excel (version 2003) and SPSS statistic software (version 
16.0). All imaging studies were analyzed independently 
and the evaluators were blinded to the clinical outcome by 
using standardized software (picture archiving and com-
munication system [PACS]). Tumor volume was calculated 
based on the diameter method (tumor volume = 4/3 * p * 
1/2x * 1/2y * 1/2z), where x, y, and z are the maximum di-
ameters in the 3 axes. Mean values are presented ± SDs.
Results
Intraoperative Imaging Studies
Intraoperatively, a mean of 2.2 ± 0.53 imaging studies 
(median 2, range 1–4 imaging studies) were performed per 
case (Table 4). There was an iMR imaging session at the 
beginning of surgery in all cases, and in all cases a second 
iMR imaging study was performed before closing (Figs. 
1 and 2 [illustrative case]). In 8 cases (20.5%), the second 
iMR imaging study revealed a tumor remnant, and further 
tumor removal was performed. In 7 of those 8 cases, a third 
imaging study was done. In 1 case, the third iMR imaging 
study revealed a tumor remnant, even after further tumor 
removal, that could not be safely resected;  the remnant was 
therefore left in place. Of the 8 patients with additional tu-
mor removal after the second iMR imaging session, 7 were 
considered free of tumor remnants after the second iMR 
imaging study. Five (71.4%) of those 7 patients showed tu-
mor remnant on 3-month diagnostic follow-up high-field 
MR imaging studies. The median tumor remnant size in 
these patients was 4 mm3 (range 4–147 mm3). In compari-
son, only 2 (6.4%) of 31 patients who were considered free 
of tumor remnants after the first intraoperative imaging 
study showed a tumor remnant at the 3-month follow-up. 
In 2 patients (5.1%) in whom residual tumor was found on 
iMR imaging, the lesion was subsequently resected, and 
this led to endocrinological remission. 
Duration of Surgical Procedures
The median duration of the surgical procedure, in-
cluding iMR imaging, was 90 minutes (mean 91.7 minutes, 
range 30–235 minutes). Table 5 shows that the median 
duration of operations in patients with previous surgery 
(105 minutes, range 60–235 minutes) was longer than in 
patients with first-time surgery (median 88 minutes, range 
30–180 minutes). The median duration of operations in pa-
tients with infiltration of the cavernous sinus (118 minutes, 
range 55–235 minutes) was prolonged in comparison with 
patients without infiltration (median 72.5 minutes, range 
30–170 minutes). Acquisition of iMR images was respon-
sible for interruption of the surgical procedure for between 
5 and 10 minutes, depending on the different sequences. 
On average this added up to approximately 25 minutes, in-
cluding 1 e-steady and 3 T1-weighted contrast-enhanced 
MR imaging studies. 
TABLE 2: Characteristics of 37 patients with acromegaly*
Characteristic Value
no. of ops 39
median pt age, in yrs 46 [19–76]
male sex 24 (61.5%)
pts w/ previous pituitary op 5 (12.8%)
median preop tumor size, in mm3 1319 [50–56,549]
infiltration of CS 10 (25.6%)
pts w/ microadenoma 10 (25.6%)
pts w/ macroadenoma 27 (69.2%)
pts w/ giant adenoma 2 (5.1%)
pts w/ symptoms of acromegaly 37 (94.8%)
pts w/ cranial nerve palsy 8 (20.5%)
*  Numbers in brackets represent the range of values throughout. Ab-
breviation: CS = cavernous sinus. 
TABLE 3: Median hormone levels pre- and postoperatively
Hormone
Level
Preop Postop
GH, in μg/L 19.50 [1.34–438.00] 1.52 [0.04–6.23]
IGF-I, in μg/L 801 [140–1349] 282 [19–835]
cortisol, in nmol/L 376 [70–979] 363 [96–808]
TSH, in mU/L 1.63 [0.14–4.71] 1.59 [0.02–6.12]
fT4, in pmol/L 15.40 [9.90–20.30] 16.90 [11.90–22.00]
testosterone, in nmol/L 8.80 [3.30–19.40] 12.30 [2.60–20.60]
PRL, in μg/L 13.50 [3.00–52.30] 9.00 [2.30–227.00]
TABLE 4: Results of surgical procedures and follow-up*
Variable Value
median iMRI studies per pt 2 [1–4]
additional tumor removal after iMRI study for resection 
 control
8 (20.5%)
visible tumor remnant at end of op 1 (2.6%)
median duration of op, in min 90 [30–235]
tumor remnant at 3-mo FU 8 (20.5%)
mean time of overall FU, in mos 29 [9–56]
median days of hospitalization 7 [5–17]
pts w/ normalized hormone levels 30 (76.9%)
pts in remission 26 (66.7%)
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Postoperative Course and Complications
The patients’ median time of hospitalization was 7 days 
(range 5–17 days). The immunohistological examination re-
vealed variable GH-positive adenoma tissue in all cases.
Postoperatively, 1 patient developed signs of CSF rhi-
norrhea and needed lumbar drainage for 5 days. Another 
patient developed diabetes insipidus and needed tempo-
rary treatment with desmopressin. There was no case of 
major postoperative hemorrhage or other complications 
needing a repeat operation.
Endocrinological Outcome 
All patients were seen for endocrinological follow-up 
4 weeks after surgery, and for surgical follow-up in the hos-
Fig. 1.  Flowchart of residual tumor detection in diagnostic high-field MR imaging and iMR imaging. 
Fig. 2. Illustrative case. A: Preoperative coronal 1.5-T MR image. B: Coronal iMR image obtained before skin incision. 
All iMR imaging was performed with the PoleStar N20 unit.  C: Coronal resection control iMR image obtained after tumor re-
moval, showing residual tumor.  D: Coronal iMR image obtained after at the end of the surgical procedure, showing no residual 
tumor. E: Postoperative coronal 1.5-T MR image.
D. Bellut et al.
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pital’s outpatient department after 12 weeks. At follow-up, 
there were 30 cases (76.9%) with normalization of preop-
erative GH and IGF-I excess. Applying the definition of 
remission according to the international consensus confer-
ence, the remission rate in our study patients was 66.7%. 
As shown in Table 3, the GH level dropped from a median 
of 19.50 mg/L (range 1.34–438.00 mg/L) preoperatively to a 
median of 1.52 mg/L (range 0.04–6.23 mg/L) at first follow-
up (see Fig. 3). The IGF-I level dropped from a median of 
801 mg/L (range 140–1349 mg/L) preoperatively to a me-
dian of 282 mg/L (range 19–835 mg/L) postoperatively. The 
other examined hormones remained at approximately their 
preoperative levels. The median level of cortisol was 376 
nmol/L (range 70–979 nmol/L) at baseline and it was 363 
nmol/L (range 96–808 nmol/L) after surgery. The median 
TSH level was 1.63 mU/L (range 0.14–4.71 mU/L) preop-
eratively and it was 1.59 mU/L (range 0.02–6.12 mU/L) 
postoperatively. The median PRL level was 13.50 mg/L 
(range 3.00–52.30 mg/L) before surgery and it was 9.00 
mg/L (range 2.30–227.00 mg/L) after surgery. The median 
fT4 value was 15.40 pmol/L (range 9.90–20.30 pmol/L) 
before and 16.90 pmol/L (range 11.90–22.00 pmol/L) after 
surgery. There was no patient in need of cortisol or T4 (thy-
roxine) substitution postoperatively who had not received 
replacement therapy before.
Regarding gonadal function, the median testosterone 
level in male patients was 8.8 nmol/L (range 3.3–19.4 
nmol/L) before and 12.3 nmol/L (range 2.6–20.6 nmol/L) 
after surgery. Three male patients were receiving testos-
terone replacement therapy at evaluation for surgery, and 
they remained gonadotropin deficient postoperatively. 
Eight female patients were postmenopausal at the time 
of surgery; in all of them, gonadotropin levels remained 
high following surgery. There was 1 female patient with 
insufficient menstrual function, and she also required es-
trogen replacement therapy following surgery.
In patients undergoing surgery for the first time, a 
remission rate of 73.5% was achieved, whereas in patients 
with previous surgery a 20% remission rate was found 
(Table 6). Patients referred for primary surgery without 
postoperative remission had higher mean baseline lev-
els of GH and larger tumor volume (54.18 mg/L [range 
1.44–438.00 mg/L] and 7181 mm3 [range 132–56,549 
mm3], respectively) compared with patients subsequently 
experiencing remission (26.42 mg/L [range 1.34–107.00 
mg/L] and 1449 mm3 [range 50–4576 mm3], respectively). 
Of the 26 patients in remission, there were only 3 (11.5%) 
with infiltration of the cavernous sinus, whereas 7 (53.8%) 
of 13 patients not in remission presented with infiltration 
of the cavernous sinus. There were no differences in gen-
eral patient data, clinical symptoms, and IGF-I levels pre-
operatively between the patients who were in remission 
and those who were not.
Regarding the Hardy classification,18 there were 11 pa-
tients in Stage A, 11 in Stage B, 12 in Stage C, 3 in Stage D, 
and 2 patients in Stage E. Remission rates were 72.3% for 
both Stages A and B patients, 75.0% for Stage C patients, 
0.0% for Stage D patients, and 50.0% for Stage E patients.
Neuroradiological Follow-Up
At the 3-month follow-up there was no tumor rem-
nant visible in diagnostic high-field MR imaging in 31 
cases (79.5%; Table 6). Of those 31 cases, 26 fulfilled the 
definition of remission. In 5 patients there was no residual 
tumor detectable in high-field diagnostic MR imaging, 
but those patients still showed elevated GH levels and 
clinical symptoms of acromegaly. There were 8 patients 
with detectable residual tumor on diagnostic follow-up 
MR imaging; 1 of those residual tumors was detected 
with iMR imaging in a patient in whom the remnant was 
TABLE 5: Patient parameters with potential influence on duration 
of surgical procedures
Comparisons Btwn Pt Groups Duration of Op, in Min
median in pts w/ first-time op vs pts 
 w/ previous op
88 [30–180] vs 105 [60–235]
median in pts in remission vs pts not 
 in remission
72.5 [40–180] vs 105 [30–235]
median in pts w/ infiltration vs pts w/o 
  infiltration of CS
118 [55–235] vs 72.5 [30–170]
Fig. 3.  Chart showing GH levels (in mg/L) before and after surgery 
for 37 patients (log scale).
TABLE 6: Data in patients with first-time surgery versus patients 
with previous surgery
Parameter First-Time Op Pts w/ Previous Op
no. of pts 34 5
median preop tumor vol, in 
 mm3
1572 [50–13,722] 308 [168–56,549]
pts w/ intraop remnant re- 
 moval
6 (17.6%) 2 (40%)
pts w/o residual tumor at FU 29 (85.3%) 2 (40%)
pts w/ tumor remnant at FU 5 (14.7%) 3 (60%)
median size of tumor rem- 
 nant, in mm3
4 [4–168] 52 [52–4691]
pts w/ intraop/postop compli- 
 cations
0 (0.0%) 1 (20%)
pts in remission 25 (73.5%) 1 (20.0%)
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left intentionally because of the impossibility of complete 
removal due to large tumor size (54 × 50 × 40 mm3), in-
filtration of the cavernous sinus, caging of the internal ca-
rotid and anterior cerebral arteries, and extensive growth 
into the hypothalamic region. The median residual tumor 
volume in those patients was 4 mm3 (range 4–168 mm3) 
in 5 patients after first-time surgery, and 52 mm3 (range 
52–4691 mm3) for 3 patients with multiple previous sur-
geries. Interestingly, diagnostic high-field MR imaging 
did not show residual tumor in 5 of 13 patients who were 
not in remission.
Discussion
This study shows for the first time a series of 39 con-
secutive cases in which patients received transsphenoidal 
iMR imaging–guided surgery for GH-producing pituitary 
adenoma by applying an ultra-low-field iMR imaging mo-
dality (PoleStar N20 unit). Our results show an overall re-
mission rate of 66.7%. In patients without previous surgery 
the remission rate was even higher (73.5%), and in previ-
ously treated patients the remission rate dropped to 20%. 
These results are at least as good as previously published 
series in the literature that show a range of overall remis-
sion rates between 42% and 82%.1,2,5–7,11,13,15,17,19,21,25,29,30,33–
35 However, in these publications the applied definition of 
remission differs widely (GH between < 1.0 mg/L and < 
5.0 mg/L). Definition of remission in our study was ap-
plied according to the international consensus confer-
ence. Studies with a comparable definition of remission 
showed remission rates ranging from 52% to 67%.5,25,29
Operations in patients with previous pituitary surgery 
showed a lower rate of remission (20.0%) than did opera-
tions in patients with primary surgery. Such findings are 
in accordance with the literature, in which remission rates 
between 20% and 30% are shown.13,14,24,29
Among the patients not in remission, there were an 
additional 5 patients (12.8%) with improvement or remis-
sion of clinical symptoms and reduction of GH excess to 
levels below 2.0 mg/L, even though these patients were 
not defined as being in remission.
There have been few previous publications in which 
intraoperative MR imaging was used for tumor resec-
tion control in pituitary surgery for acromegaly.4,14,16,32 
Fahlbusch et al.14 published a series of patients in whom 
operations were performed with the assistance of 1.5-T 
iMR imaging studies, and these investigators reported re-
mission in 10 (44%) of 23 patients. Although the results 
of our study appear to compare well with those reported 
by Fahlbusch et al., patient characteristics in the 2 small 
groups may not be fully comparable, and because these 
considerably influence the surgical outcome, any claim of 
superiority between these 2 studies would be premature. 
In a study by Gerlach et al.,16 only some of the patients an-
alyzed had GH-positive adenomas. The complication rate 
and neuroradiological tumor remnants were comparably 
low, but endocrinological assessment was not performed.
Intraoperative imaging studies acquired with the 
ultra-low-field MR imaging unit PoleStar N20 gave valu-
able and accurate information regarding tumor remnants 
after removal. Only in 2 cases was there a false-negative 
interpretation regarding tumor remnants after the first 
iMR imaging study for resection control. Detection of a 
tumor remnant led to an increase of 5.1% in remission 
rate, because there were 2 patients in remission in whom 
residual tumor that was found on iMR imaging could be 
completely resected. Despite this 5.1% increase in the re-
mission rate, we could only identify residual tumor with 
iMR imaging in 1 of 8 patients with tumor remnants on 
the diagnostic follow-up MR imaging. Interestingly, the 
diagnostic high-field MR imaging was unable to visual-
ize residual tumor in 5 of 13 patients who were not en-
docrinologically in remission. This indicates that even 
under optimal conditions, as in a diagnostic MR imag-
ing environment, in 5 (12.8%) of 39 patients in the whole 
study group, visualization of residual tumor could not be 
achieved, pointing to a systematic limitation of MR imag-
ing for resection control.
Although the iMR imaging system was thought to be 
useful and led to improved remission rates, the following 
limitations have to be considered. As in cases with addi-
tional tumor removal after iMR imaging studies follow-
ing resection of the adenoma, there was a higher rate of 
false-negative results regarding tumor remnants. In these 
7 of 8 cases with small adenoma remnants on postopera-
tive diagnostic MR imaging, a high rate (50%) of cavern-
ous sinus tumor infiltration was present. This illustrates 
the limited visualization of tumor remnants in the cav-
ernous sinus, as mentioned in previous studies.24 Because 
remission rates in patients with recurring disease were 
only 20%, it has to be stated that iMR imaging in this 
difficult population was not as useful as in patients with 
first-time pituitary surgery. This may be partially caused 
by the insufficient differentiation of scar and recurrent 
adenoma tissue. High-field iMR imaging systems and 
imaging sequences with higher resolution of details may 
lead to a better definition of these structures; however, an 
improved patient outcome with the use of high-field iMR 
imaging has not yet been demonstrated. Whether the 
costs related to iMR imaging systems used in pituitary 
surgery are compensated by improved outcome has to be 
shown by future investigations.
The surgical procedures described were safe. There 
was only 1 patient who developed signs of persistent CSF 
rhinorrhea and needed lumbar drainage for 4 days. Com-
parison with previously published studies showed rates 
of severe complications in up to 8% of cases and CSF 
rhinorrhea in approximately 2% of cases.1,14,29 One patient 
developed transient diabetes insipidus and needed tempo-
rary treatment with desmopressin. This type of surgery 
appears to be quite safe for the remaining healthy pitu-
itary cells; in fact, patients did not develop pituitary fail-
ure (even gonadotropin and sex hormone deficiency was 
rare), as confirmed in the follow-up evaluation of these 
patients. Overall, the complication rate was low and there 
were no severe complications such as postoperative hem-
orrhages, meningitis, or injury to cranial nerves.
Since the year 2000, all patients with pituitary ade-
nomas in our department underwent operation with the aid 
of iMR imaging, and therefore a comparison with patients 
who underwent operations without iMR imaging was not 
found to be adequate; this is a limitation of this study.
D. Bellut et al.
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Conclusions
In this largest study to date of GH-producing pitu-
itary adenomas analyzed using iMR imaging–guided 
transsphenoidal surgery, the results presented suggest 
that this method is a highly effective and safe treatment 
modality, even compared with previously published sur-
gical series in which high-field iMR imaging was used. 
The overall remission rate of 66.7%, and even 73.5% for 
patients without previous surgery, and the lack of com-
plications requiring additional surgery underscore this 
statement. Limitations of iMR imaging are the detection 
of small remnants in the cavernous sinus and persisting 
disease that could not be observed, even on diagnostic 
high-field follow-up MR images. Further analysis points 
to a systematic limitation of iMR imaging with regard to 
remission rates beyond 80%, because even high-field MR 
imaging under ideal conditions could not detect residual 
tumor in 13% of cases. Detection of tumor remnant with 
iMR imaging and additional tumor removal led to a 5.1% 
increase of the remission rate.
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